Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobitolimod in left-sided ulcerative colitis
NCT04985968Phase 3Terminated
- Sponsor
- InDex Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Dec 2023
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of cobitolimod in ulcerative colitis (UC), sponsored by InDex Pharmaceuticals. Primary endpoint: Proportion of participants with clinical remission at 6 weeks. Started Nov 2021; status: terminated.
02
Drugs
cobitolimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04985968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985968.